US · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 1.87 against a street estimate of 1.84 — a beat of 1.6%.
Analysts rate Zoetis Inc a buy (12 buy, 8 hold, 0 sell out of 20) with an average price target of $96.00.
CAUTIOUS Q2 revenue flat, earnings down 2% organically. U.S. Companion Animal collapsed 11% amid clinic visit declines and intense competition. Livestock +11% and Diagnostics +12% provided offset. Full-year guidance slashed to -3% to +1% revenue, -9% to -5% earnings. Management deploying aggressive gross-to-net promotions to defend share. Q2 2026 U.S. Companion Animal pressured by clinic dynamics and affordability; International buoyed by emerging markets growth across Livestock, Companion Animal, and Diagnostics. Analysts pressed on pricing mechanics (gross-to-net vs. ASP), duration of promotions, and competitive product differentiation. Management clarified gross-to-net is targeted/time-bound rebates and bundling, not list-price cuts; acknowledged affordability crisis reduces 'good enough' threshold; indicated pullback only after share stabilizes, likely 6–18 months. 2026-08-06…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 8.61% |
| Vanguard Capital Management, LLC | 6.31% |
| Vanguard Portfolio Management, LLC | 5.80% |
| State Street Corp | 4.68% |
| State Farm Mutual Automobile Ins Co | 3.85% |
| Morgan Stanley - Brokerage Accounts | 3.42% |
| Geode Capital Management, LLC | 2.75% |
| Wellington Management Company LLP | 2.28% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 ZOETIS INC. — FORM 10-Q SUMMARY (Q2 2026) HEADLINE NUMBERS • Revenue (6 months): $4,730 million vs. $4,672 million prior year (+1.2%) • Revenue (Q2) | 2026-08-06 |
| Board / officer change · Q3 2026 ZOETIS INC. - 8-K SUMMARY (AUGUST 6, 2026) HEADLINE NUMBERS • James Saccaro appointed as Executive Vice President, Chief Financial Officer and Chief | 2026-08-06 |
| Results announced · Q3 2026 ZOETIS INC. – Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q2 2026 Revenue: $2.5 billion, flat vs. Q2 2025 on reported basis; down 1% on organic oper | 2026-08-06 |
| Board / officer change · Q2 2026 ZOETIS INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting held May 20, 2026 with 379,034,516 shares present (90.13% of voting power) • 12 dir | 2026-05-22 |
| Reg FD disclosure · Q2 2026 ZOETIS INC. - FORM 8-K SUMMARY (MAY 20, 2026) HEADLINE NUMBERS • Dividend declared: $0.53 per share for Q3 2026 • Payment date: September 1, 2026 • | 2026-05-20 |
| Quarterly report · Q1 2026 ZOETIS INC. – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Total Revenue Q1 2026: $2,262 million (up from $2,198 million in Q1 2025; +2.9% increase) • Ne | 2026-05-07 |
| Proxy statement · Q4 2025 ZOETIS INC. 2026 PROXY STATEMENT SUMMARY CEO COMPENSATION • Kristin C. Peck (CEO) total compensation for 2025: Not explicitly stated in this excerpt | 2026-04-08 |
| Annual report FY2025 ZOETIS INC. – FORM 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Total 2025 Revenue: $9,351 million (U.S. $5,097 million + International $4,2 | 2026-02-12 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | $0.53 / share ex-date Jul 20, 2026 · pay Sep 1, 2026 | 2026-07-20 |
| Dividend | $0.53 / share ex-date Apr 20, 2026 · pay Jun 2, 2026 | 2026-04-20 |
| Dividend | $0.53 / share ex-date Jan 20, 2026 · pay Mar 3, 2026 | 2026-01-20 |
| Dividend | $0.50 / share ex-date Oct 31, 2025 · pay Dec 2, 2025 | 2025-10-31 |
| Announcement | Date |
|---|---|
| Full year 2026 guidance provided with Q2 2026 financial results Zoetis Inc. filed an 8-K on August 6, 2026, announcing its second quarter 2026 financial results and providing updated guidance for full year 2026. The filing itself contains no specific fin | 2026-08-06 |
| Q1 2026 results reported and full year 2026 guidance provided Zoetis Inc. filed an 8-K on May 7, 2026 to disclose its first quarter 2026 financial results and provide full-year 2026 guidance. This is a routine earnings announcement filing. The 8-K itse | 2026-05-07 |
| Financial results for 2025 and guidance provided for full year 2026 Zoetis Inc., an animal health company, issued a press release on February 12, 2026, announcing its financial results for Q4 and full year 2025, along with guidance for 2026. This 8-K filing | 2026-02-12 |
| Q3 2025 results and updated full year 2025 guidance announced Zoetis Inc. filed an 8-K on November 4, 2025, announcing its third quarter 2025 financial results and providing updated guidance for the full year 2025. The 8-K itself contains no specific f | 2025-11-04 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Zoetis Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.